Morgan Stanley published a research report stating thatchristmascarolmegaways, Kangfang Biotech's share price has a 70% to 80% chance of rising in the next 30 days, with a target price of HK$64, giving it an "overweight" rating.
The bank explained that it was because Kangfang Biotech's AK112 -303 drug was approved by the State Food and Drug Administration to treat refractory patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The above drugs are approved by the mainlandchristmascarolmegawaysThe second bispecific antibody drug was developed by Kangfang Biotech. As a result, Morgan Stanley maintains its basic expectation for the successful performance of the operating income of the above-mentioned drugs and believes that the current stock price level should become a favorable entry point.